© 2014 Gupta et al.; licensee BioMed Central Ltd.Background: Psoriasis is a multifactorial, chronic disease of skin affecting 2-3% of the world's population. Genetic studies of psoriasis have identified a number of susceptibility genes that are involved in

Cornelia de Lange Syndrome (CdLS) is a severe developmental disorder frequently associated with heterozygous loss-of-function NIPBL mutations. NIPBL loads cohesin onto chromatin. Cohesin mediates sister chromatid cohesion important for mitosis, but is also increasingly being recognized as a regulator of gene expression. In CdLS patient cells and animal models, the presence of multiple gene expression changes with little or no cohesion defect suggests that disruption of gene regulation underlies this disorder. However, the effect of NIP BL haploinsufficiency on cohesin binding, and how this relates .to the clinical presentation of CdLS, has not been fully investigated. We examined genome-wide cohesin binding and its relationship to gene expression using mouse embryonic fibroblasts (MEFs) from Nipbl +I- mice that recapitulate the CdLS phenotype. We found a global decrease in cohesin binding, including those at CTCF sites and repeat regions. Cohesin-bound genes are enriched for H3K4me3 at the promoters and are mostly downregulated in Nipbl mutant MEFs with evidence for reduced promoter- enhancer interaction, suggesting that gene activation is the primary co he sin function sensitive to Nip bl reduction. Over 50% of genes affected in mutant MEFs are cohesin target genes, including those involved in adipogenesis, indicating their direct contributions to the Nipbl haploinsufficiency-induced CdLS phenotype. Interestingly, mutations in several cohesin subunit genes exhibit mild and somewhat distinct phenotypes compared to that of NIP BL haploinsufficiency, raising the possibility that NIPBL may have unique functions independent of cohesin. We will discuss our recent findings that su11port the notion that the cohesin-independent role ofNIPBL also contributes to the CdLS pathogenesis. This work was supported in part by NIH grants P01-HD052860 and R21 HD062951.

Newborn screening (NBS) prevents morbidity and mortality by screening babies for selected disorders in the first days of life so that early diagnosis and treatment can be initiated. Congenital disorders impact an estimated 8 million or 6% of annual births worldwide, and of the top five that contribute 25% to the global burden of these disorders, three can be identified and managed by NBS. There are determined pockets of activity in Latin America, Sub-Saharan Africa, and the Asia Pacific region, where partnerships among government, non-governmental organizations, academia, the private sector and civil society are developing novel NBS programs that are both saving lives and preventing disability in those who survive.